These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 9850039)
1. Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer. Atkins CD J Clin Oncol; 1998 Dec; 16(12):3916-7. PubMed ID: 9850039 [No Abstract] [Full Text] [Related]
2. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715 [TBL] [Abstract][Full Text] [Related]
3. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan. Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y; Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284 [TBL] [Abstract][Full Text] [Related]
4. Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer. Amadori D; Silvestrini R; De Lena M; Boccardo F; Rocca A; Scarpi E; Schittulli F; Brandi M; Maltoni R; Serra P; Ponzone R; Biglia N; Gianni L; Tienghi A; Valerio MR; Bonginelli P; Amaducci L; Faedi M; Baldini E; Paradiso A Breast Cancer Res Treat; 2011 Feb; 125(3):775-84. PubMed ID: 21132360 [TBL] [Abstract][Full Text] [Related]
5. Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer. Radice D; Redaelli A Pharmacoeconomics; 2005; 23(1):69-75. PubMed ID: 15693729 [TBL] [Abstract][Full Text] [Related]
6. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N; J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958 [TBL] [Abstract][Full Text] [Related]
7. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study. Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D; J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656 [TBL] [Abstract][Full Text] [Related]
8. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217 [TBL] [Abstract][Full Text] [Related]
9. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial]. Ost E; Illiger HJ Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396 [No Abstract] [Full Text] [Related]
10. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. Piccart MJ; Di Leo A; Beauduin M; Vindevoghel A; Michel J; Focan C; Tagnon A; Ries F; Gobert P; Finet C; Closon-Dejardin MT; Dufrane JP; Kerger J; Liebens F; Beauvois S; Bartholomeus S; Dolci S; Lobelle JP; Paesmans M; Nogaret JM J Clin Oncol; 2001 Jun; 19(12):3103-10. PubMed ID: 11408507 [TBL] [Abstract][Full Text] [Related]
11. Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Ejlertsen B; Mouridsen HT; Jensen MB; Andersen J; Cold S; Edlund P; Ewertz M; Jensen BB; Kamby C; Nordenskjold B; Bergh J Eur J Cancer; 2007 Mar; 43(5):877-84. PubMed ID: 17306974 [TBL] [Abstract][Full Text] [Related]
12. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820 [TBL] [Abstract][Full Text] [Related]
13. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Gogas H; Dafni U; Karina M; Papadimitriou C; Batistatou A; Bobos M; Kalofonos HP; Eleftheraki AG; Timotheadou E; Bafaloukos D; Christodoulou C; Markopoulos C; Briasoulis E; Papakostas P; Samantas E; Kosmidis P; Stathopoulos GP; Karanikiotis C; Pectasides D; Dimopoulos MA; Fountzilas G Breast Cancer Res Treat; 2012 Apr; 132(2):609-19. PubMed ID: 22187126 [TBL] [Abstract][Full Text] [Related]
14. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. de Azambuja E; Ameye L; Diaz M; Vandenbossche S; Aftimos P; Bejarano Hernández S; Shih-Li C; Delhaye F; Focan C; Cornez N; Vindevoghel A; Beauduin M; Lemort M; Paesmans M; Suter T; Piccart-Gebhart M Eur J Cancer; 2015 Nov; 51(17):2517-24. PubMed ID: 26321502 [TBL] [Abstract][Full Text] [Related]
15. Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial. Kümmel S; Krocker J; Kohls A; Breitbach GP; Morack G; Budner M; Blohmer JU; Lichtenegger W; Elling D Crit Rev Oncol Hematol; 2006 May; 58(2):166-75. PubMed ID: 16387512 [TBL] [Abstract][Full Text] [Related]
16. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595 [TBL] [Abstract][Full Text] [Related]
17. TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients. Hertel PB; Tu D; Ejlertsen B; Jensen MB; Balslev E; Jiang S; O'Malley FP; Pritchard KI; Shepherd LE; Bartels A; Brünner N; Nielsen TO Breast Cancer Res Treat; 2012 Feb; 132(1):225-34. PubMed ID: 22160637 [TBL] [Abstract][Full Text] [Related]
18. [Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast cancer]. Noël G; Mazeron JJ Cancer Radiother; 2001 Apr; 5(2):206-7. PubMed ID: 11355592 [No Abstract] [Full Text] [Related]
19. Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group. Eiermann W; Graf E; Ataseven B; Conrad B; Hilfrich J; Massinger-Biebl H; Vescia S; Loibl S; von Minckwitz G; Schumacher M; Kaufmann M; Eur J Cancer; 2010 Jan; 46(1):84-94. PubMed ID: 19879750 [TBL] [Abstract][Full Text] [Related]
20. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]